Investigational strategies in chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 18, Issue 3, 2004, Pages 619-639

  Cortes, Jorge E ^a   O'Brien, Susan M ^a   Giles, Francis ^a   Alvarez, Ricardo H ^a   Talpaz, Moshe ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; AG 957; ALKALOID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AZACITIDINE; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CYTARABINE; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; IMATINIB; LONAFARNIB; MIDOSTAURIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEGINTERFERON ALPHA2A; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VALPROIC ACID; VATALANIB; VORINOSTAT;

BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; METHYLATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT FAILURE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ARSENICALS; CANCER VACCINES; DNA METHYLATION; ENZYME INHIBITORS; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; OXIDES; PIPERAZINES; PYRIMIDINES; RESEARCH; TREATMENT OUTCOME;

EID: 3242779326     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.03.004     Document Type: Review

References (143)

1. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652
2. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 101:2003;97-100
3. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004
4. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937
5. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 8:2002;2167-2176
6. Kantarjian H.M., Cortes J., O'Brien S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 99:2002;3547-3553
7. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539
8. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566
9. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037
10. Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood. 101:2003;473-475
11. Cortes J., Giles F., O'Brien S., et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-{alpha}. Blood. 102:2003;83-86
12. Cortes J., O'Brien S., Talpaz M., et al. Clinical significance of molecular response in chronic myeloid leukemia after imatinib (Gleevec) therapy: low levels of residual disease predict for response duration. Blood. 102:2003;416a. Abstract 1513
13. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 103:2004;2873-2878
14. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 96:2000;3195-3199
15. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 97:2001;1999-2007
16. Scappini B., Onida F., Kantarjian H.M., et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 94:2002;2653-2662
17. Kantarjian H.M., Smith T., O'Brien S., et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 122:1995;254-261
18. Kantarjian H.M., O'Brien S., Smith T.L., et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 17:1999;284-292
19. Guilhot F., Chastang C., Michallet M., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group [comments]. N Engl J Med. 337:1997;223-229
20. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 97:2003;1033-1041
21. O'Dwyer M.E., Mauro M.J., Kuyl J.M., et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood. 98:2001;846a. Abstract 3513
22. Talpaz M., O'Brien S., Rose E., et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 98:2001;1708-1713
23. Hochhaus A., Fischer T., Bruemmendorf T., et al. Combination therapy of chronic myelogenous leukemia with imatinib and pegylated interferonα2a. Proc Am Soc Clin Oncol. 22:2003;569. Abstract 2287
24. Baccarani M., Rosti G., Trabacchi E., et al. Imatinib and pegylated-α2b interferon in early chronic phase Ph+ chronic myeloid leukemia: 12-months results of a prospective phase I/II study by the Italian Cooperative Study Group on CML. Blood. 102:2003;183a. Abstract 638
25. Martine G., Philippe R., Michel T., et al. Imatinib (Gleevec) and cytarabine (ara-C) is an effective regimen in Philadelphia-positive chronic myelogenous leukemia chronic phase patients. Blood. 100:2002;95a. Abstract 351
26. Mauro M.J., O'Dwyer M., Stone R.M., et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low-dose ara-C as initial therapy for newly diagnosed chronic phase CML. Blood. 100:2002;165a. Abstract 617
27. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 134:2001;573-586
28. Baylin S.B., Herman J.G., Graff J.R., et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72:1998;141-196
29. Laird P.W., Jackson-Grusby L., Fazeli A., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 81:1995;197-205
30. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 95:2000;2990-2992
31. Asimakopoulos F.A., Shteper P.J., Krichevsky S., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 94:1999;2452-2460
32. Issa J.P., Kantarjian H., Mohan A., et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 93:1999;2075-2080
33. Zion M., Ben-Yehuda D., Avraham A., et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 91:1994;10722-10726
34. Roman-Gomez J., Castillejo J.A., Jimenez A., et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol. 21:2003;1472-1479
35. Wijermans P., Lubbert M., Verhoef G., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 18:2000;956-962
36. Kornblith A.B., Herndon J.E. II, Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 20:2002;2441-2452
37. Kantarjian H.M., O'Brien S., Cortes J., et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 98:2003;522-528
38. Issa J.P., Garcia-Manero G., Mannari R., et al. Minimal effective dose of hypomethylating agent decitabine in hematopoietic malignancies. Blood. 98:2001;594a
39. La Rosee P., Johnson K., Moseson E.M., et al. Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents. Blood. 98:2001;839a
40. La Rosee P., Johnson K., Corbin A.S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl positive cell lines. Blood. 103:2004;208-215
41. Thiagalingam S., Cheng K.H., Lee H.J., et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 983:2003;84-100
42. Timmermann S., Lehrmann H., Polesskaya A., et al. Histone acetylation and disease. Cell Mol Life Sci. 58:2001;728-736
43. Nimmanapalli R., Fuino L., Stobaugh C., et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101:2003;3236-3239
44. Yu C., Rahmani M., Almenara J., et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63:2003;2118-2126
45. Nimmanapalli R., Fuino L., Bali P., et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63:2003;5126-5135
46. Tamanoi F., Gau C.L., Jiang C., Edamatsu H., Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci. 58:2001;1636-1649
47. Ashar H.R., James L., Gray K., et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 275:2000;30451-30457
48. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 19:1999;1831-1840
49. Cortes J.E., Kurzrock R., Kantarjian H.M. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 39:2002;26-30
50. Kurzrock R., Kantarjian H.M., Cortes J.E., et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting. Blood. 102:2003;4527-4534
51. Kurzrock R., Cortes J.E., Ryback M.E., et al. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood. 98:2001;848a
52. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369
53. Lancet J.E., Karp J.E., Gotlib J., et al. Zarnestra (R115777) in previously untreated poor-risk AML and MDS: preliminary results of a phase II trial. Blood. 100:2002;560a. Abstract 2200
54. Peters D.G., Hoover R.R., Gerlach M.J., et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97:2001;1404-1412
55. Reichert A., Heisterkamp N., Daley G.Q., et al. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 97:2001;1399-1403
56. Hoover R.R., Mahon F.-X., Melo J.V., et al. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 98:2001;617a
57. Nakajima A., Tauchi T., Sumi M., et al. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther. 2:2003;219-224
58. Cortes J., Albitar M., Thomas D., et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 101:2003;1692-1697
59. Thomas D., Cortes J., O'Brien S., et al. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia. Blood. 98:2001;727a
60. Cortes J., Daley G.Q., Talpaz M., et al. Pilot study of SCH66336 (lonafarnib), a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib. Blood. 100:2002;164a. Abstract 614
61. Cortes J., Garcia-Manero G., O'Brien S., et al. Phase I study of imatinib and tipifarnib (Zarnestra, R115777) in patients with chronic myeloid leukemia in chronic phase refractory to imatinib. Blood. 102:2003;909a. Abstract 3383
62. Gotlib J., Mauro M.J., O'Dwyer M., et al. Tpipifarnib (Zarnestra) and imatinib (Gleevec) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a phase I study. Blood. 102:2003;909a. Abstract 3384
63. Cortes J., O'Brien S., Ferrajoli A., et al. Phase I study of imatinib and lonafarib (SCH66336) in patients with chronic myeloid leukemia refractory to imatinib. Blood. 102:2003;909a. Abstract 3382
64. Anonymous Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chinese Medical Journal. 3:1977;319-324
65. Ye J.S., Wang X.H., Feng G.H., et al. Small-dose harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia. 2:1988;427-429
66. O'Brien S., Kantarjian H., Keating M., et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 86:1995;3322-3326
67. Kantarjian H.M., Talpaz M., Smith T.L., et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 18:2000;3513-3521
68. Visani G., Russo D., Ottaviani E., et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 11:1997;624-628
69. O'Brien S., Kantarjian H., Koller C., et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 93:1999;4149-4153
70. O'Brien S., Giles F., Talpaz M., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 98:2003;888-893
71. Scappini B., Onida F., Kantarjian H., et al. In vitro effects of STI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells. Blood. 96:2000;99a
72. Chen R., NBenaissa S., Plunkett W. A sequential blockade strategy to target the Bcr/Abl oncoprotein in chronic myelogenous leukemia with STI571 and the protein synthesis inhibitor homoharringtonine. Proc Am Assoc Cancer Res. 44:2003;34. Abstract 3788
73. Marin D., Ranger A., Kaeda J., et al. Phase I/II trial of adding semi-synthetic homoharringtonine (HHT, Myelostat) in CML patients who have achieved complete cytogenetic response on imatinib. Blood. 102:2003;908a. Abstract 3379
74. Forkner C.E., Scott T.F. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA. 97:1931;3
75. 3) in the treatment of patients with acute promyelocytic leukemia. Cancer. 97:2003;2218-2224
76. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 19:2001;3852-3860
77. Murgo A.J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 6(Suppl 2):2001;22-28
78. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:2002;1835-1837
79. Rousselot P., Labaume S., Marolleau J.P., et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 59:1999;1041-1048
80. Perkins C., Kim C.N., Fang G., et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 95:2000;1014-1022
81. Puccetti E., Guller S., Orleth A., et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 60:2000;3409-3413
82. 3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 15:2001;772-778
83. La Rosee P., Johnson K., O'Dwyer M.E., et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 30:2002;729-737
84. Mauro M.J., Deininger M.W., O'Dwyer M.E., et al. Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase. Blood. 100:2002;781a. Abstract 3090
85. 3) in patients with accelerated and blast phase CML. Blood. 102:2003;314b. Abstract 4977
86. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622
87. Rothwarf D.M., Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE. 1999:1999;RE1
88. Hamdane M., David-Cordonnier M.H., D'Halluin J.C. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene. 15:1997;2267-2275
89. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981
90. Korus M., Mahon G.M., Cheng L., et al. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene. 21:2002;4601-4612
91. Dou Q.P., McGuire T.F., Peng Y., et al. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther. 289:1999;781-790
92. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 20:2002;4420-4427
93. Gatto S., Scappini B., Pham L., et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 88:2003;853-863
94. Cortes J., Giles F., O'Brien S., et al. Phase II study of bortezomib (VELCADE, formerly PS341) for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Blood. 102:2003;312b. Abstract 4971
95. Bellamy W.T., Richter L., Frutiger Y., et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:1999;728-733
96. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 96:2000;2240-2245
97. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 97:2001;1427-1434
98. Schuch G., Machluf M., Bartsch G. Jr., et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 100:2002;4622-4628
99. Verstovsek S., Kantarjian H., Manshouri T., et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 99:2002;2265-2267
100. Verstovsek S., Lunin S., Kantarjian H., et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 27:2003;661-669
101. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103
102. Gabrilovich D.I., Ishida T., Nadaf S., et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 5:1999;2963-2970
103. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol. 40:2003;59-71
104. Guilhot F., Lacotte-Thierry L. Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther. 40:1998;237-239
105. Chen W., Peace D.J., Rovira D.K., et al. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA. 89:1992;1468-1472
106. Cullis J.O., Barrett A.J., Goldman J.M., et al. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia. 8:1994;165-170
107. Pawelec G., Max H., Halder T., et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood. 88:1996;2118-2124
108. Yotnda P., Firat H., Garcia-Pons F., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 101:1998;2290-2296
109. Pinilla-Ibarz J., Cathcart K., Korontsvit T., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:2000;1781-1787
110. Catchart K., Pinilla-Ibarz J., Korontsvit T., et al. All CML patients vaccinated with a multivalent bcr-abl peptide vaccine show specific immune responses in a phase II trial. Blood. 98:2001;728a
111. Bocchia M., Gentili S., Abruzzese E., et al. Imatinib plus CMLVAX100 (p210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia showing persistent residual disease during treatment with imatinib mesylate. Blood. 102:2003;30a. Abstract 93
112. Molldrem J., Dermime S., Parker K., et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 88:1996;2450-2457
113. Dengler R., Munstermann U., al-Batran S., et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol. 89:1995;250-257
114. Molldrem J.J., Clave E., Jiang Y.Z., et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529-2534
115. Molldrem J., Kant S., Lu S., et al. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia. Blood. 100:2002;6a
116. Pockley A.G. Heat shock proteins as regulators of the immune response. Lancet. 362:2003;469-476
117. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 269:1995;1585-1588
118. Li Z., Qiao Y., Laska E., et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia. Proc Am Soc Clin Oncol. 22:2003;166. Abstract 664
119. Donato N.J., Wu J.Y., Stapley J., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 101:2003;690-698
120. Golas J.M., Arndt K., Etienne C., et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 63:2003;375-381
121. Warmuth M., Simon N., Mitina O., et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 101:2003;664-672
122. Huron D.R., Gorre M.E., Kraker A.J., et al. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-Abl-driven K562 cells and is effective against STI571-resistant Bcr-Abl mutants. Clin Cancer Res. 9:2003;1267-1273
123. Tatton L., Morley G.M., Chopra R., et al. The Src-selective kinase inhibitor PP1 also inhibits kit and Bcr-Abl tyrosine kinases. J Biol Chem. 278:2003;4847-4853
124. Nimmanapalli R., O'Bryan E., Huang M., et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 62:2002;5761-5769
125. Svingen P.A., Tefferi A., Kottke T.J., et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res. 6:2000;237-249
126. Sun X., Layton J.E., Elefanty A., et al. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood. 97:2001;2008-2015
127. Mow B.M., Chandra J., Svingen P.A., et al. Effects of the Bcr/Abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 99:2002;664-671
128. Cirinna M., Trotta R., Salomoni P., et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood. 96:2000;3915-3921
129. Tauchi T., Sumi M., Nakajima A., et al. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 9:2003;4267-4273
130. Bhojani M.S., Rossu B.D., Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther. 2:2003;S71-S78
131. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682
132. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2:2002;420-430
133. Plasilova M., Zivny J., Jelinek J., et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 16:2002;67-73
134. Uno K., Inukai T., Kayagaki N., et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 101:2003;3658-3667
135. Hannon G.J. RNA interference. Nature. 418:2002;244-251
136. Zamore P.D. Ancient pathways programmed by small RNAs. Science. 296:2002;1265-1269
137. Scherr M., Battmer K., Winkler T., et al. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 101:2003;1566-1569
138. Wohlbold L., van der Kuip H., Miething C., et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. 102:2003;2236-2239
139. Goetz M.P., Toft D.O., Ames M.M., et al. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 14:2003;1169-1176
140. Smith D.F., Whitesell L., Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Rev. 50:1998;493-514
141. Stancato L.F., Silverstein A.M., Owens-Grillo J.K., et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem. 272:1997;4013-4020
142. Nimmanapalli R., O'Bryan E., Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 61:2001;1799-1804
143. Gorre M.E., Ellwood-Yen K., Chiosis G., et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:2002;3041-3044